['rheumatoid arthritis']
['gs-9876', 'filgotinib', 'gs-9876 placebo', 'filgotinib placebo', 'methotrexate']

        Key Inclusion Criteria:

          -  Active RA disease as defined by: a tender joint count (TJC) of ≥ 6 (out of 68), a
             swollen joint count (SJC) of ≥ 6 (out of 66) at screening and Day 1

          -  Inadequate response to treatment with oral or parenteral methotrexate (MTX) 7.5 to 25
             mg/week continuously for at least 12 weeks

          -  No evidence of active or latent tuberculosis

        Key Exclusion Criteria:

          -  Prior treatment with B-cell depleting agents (eg, rituximab), unless more than 6
             months prior to the first dose of study drug and documented return of CD19+ cells at
             screening

          -  Prior treatment with any commercially available or investigational spleen tyrosine
             kinase (SYK) inhibitor

          -  Concurrent treatment with any other conventional synthetic DMARD (csDMARD) other than
             MTX and/or hydroxychloroquine (HCQ) (prior csDMARD treatment allowed if appropriate
             wash out as defined in the protocol)

          -  Concurrent treatment with any biological disease modifying anti-rheumatic drug
             (bDMARD)(prior bDMARD treatment allowed if appropriate wash out as defined in the
             protocol). Prior failure to treatment with bDMARDs is not an exclusion criterion.

        Note: Other protocol defined Inclusion/ Exclusion criteria may apply.
      